Tag: NBE-002
Rethinking ADC Design: Lessons from NBE-002 and the Potency of PNU-159682
Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted cancer therapeutics, combining the specificity of monoclonal antibodies with the cytotoxicity of potent payloads. The development of NBE-002*, an ROR1-targeted ADC using the highly potent anthracycline derivative PNU-159682, provides valuable insights into the opportunities and challenges of ADC chemical design. By examining the story of NBE-002, we can better understand how payload potency, linker chemistry, and conjugation strategy determine both preclinical promise and clinical limitations.
NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...
Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
Boehringer Ingelheim Venture Fund and PPF Group Close a US $...
Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...
Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development
Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...
